Polymyositis Pipeline Analysis Report 2025
Description
Polymyositis is a rare autoimmune disorder characterized by chronic inflammation of the muscles, leading to progressive weakness and fatigue. According to Tippawan Onchan et al., 2024, patients with idiopathic inflammatory myopathies (IIMs), including polymyositis, have lower survival rates than the general population, with early mortality ranging between 7.8% and 45%. Current therapies focus on immunosuppressants and corticosteroids, while emerging treatments in the pipeline aim at targeted biologics and gene therapies. According to the polymyositis pipeline analysis by Expert Market Research, growing research, increased awareness, and advancements in precision medicine are expected to drive significant growth in the coming years.
Report Coverage
The Polymyositis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into polymyositis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for polymyositis. The polymyositis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The polymyositis pipeline landscape will include an analysis based on efficacy and safety measures outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with polymyositis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to polymyositis.
Polymyositis Pipeline Outlook
Polymyositis is a rare inflammatory muscle disease characterized by chronic muscle inflammation and progressive weakness, primarily affecting the shoulders, hips, and neck. The exact cause remains unknown, though immune system dysfunction is believed to trigger muscle fiber damage. Symptoms often include fatigue, difficulty swallowing, and reduced mobility, significantly impacting daily activities.
Polymyositis treatment focuses on suppressing inflammation and improving muscle strength. Standard therapies include corticosteroids, immunosuppressants, and physical therapy to manage symptoms and prevent disease progression. PF1801, a novel long-acting glucagon-like peptide-1 receptor agonist, received FDA Orphan Drug designation in September 2021. It shows potential in improving muscle function in rare inflammatory myopathies.
Polymyositis Epidemiology
According to Tippawan Onchan et al., 2024, patients with idiopathic inflammatory myopathies (IIMs) exhibit lower survival rates compared to the general population, with early mortality ranging from 7.8% to 45%. Incidence rates vary across regions, reported at 7.7 cases per million in Asia and 2.18 cases per million in Israel. Overall, the global incidence ranges from 1.16 to 19 cases per million per year, with a prevalence of 2.4 to 33.8 per 100,000.
Polymyositis – Pipeline Therapeutic Assessment
This section of the report covers the analysis of polymyositis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
The polymyositis pipeline analysis report covers 50+ drug analyses based on drug classes:
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II, with 40%, covers a major share of the total polymyositis clinical trials. It is followed by phase I at 36.73%, and phase III at 18.37%. This distribution indicates a robust pipeline, with a significant number of candidates advancing through early and mid-stage trials. The progression of these therapies holds promise for enhancing treatment options and improving patient outcomes in polymyositis.
Polymyositis Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the polymyositis pipeline analysis include small. The polymyositis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for polymyositis. Immune-targeted therapies are gaining traction in the polymyositis drug pipeline to address high unmet needs. For instance, AstraZeneca initiated the JASMINE Phase III trial in September 2024 to evaluate Saphnelo (anifrolumab) in patients with idiopathic inflammatory myopathies, including polymyositis. This therapy selectively inhibits type I interferon signaling, aiming to reduce muscle inflammation and improve patient outcomes, offering a disease-specific alternative to broad immunosuppressants and corticosteroids.
Polymyositis Clinical Trials – Key Players
The EMR report for the polymyositis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed polymyositis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in polymyositis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for polymyositis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of polymyositis drug candidates.
Drug: PF-06823859
PF-06823859, sponsored by Pfizer, is an investigational drug being evaluated in a Phase 3 study for adults with active idiopathic inflammatory myopathies, including polymyositis and dermatomyositis. The study is examining how PF-06823859, administered as an intravenous infusion every four weeks, affects muscle strength, inflammation, and overall safety. This monoclonal antibody is designed to target immune-mediated muscle damage, aiming to improve mobility and reduce disease-related muscle weakness over a 48-week treatment period.
Biological: PN-101
PN-101, sponsored by Paean Biotechnology Inc., is an innovative allogeneic mitochondrial therapy derived from umbilical cord–derived mesenchymal stem cells. This Phase 2 trial is evaluating the efficacy and safety of PN-101 in patients with refractory polymyositis or dermatomyositis. The study is examining improvements in disease activity using IMACS-TIS at Week 12 compared with a placebo. PN-101 is administered as a single intravenous dose, aiming to restore cellular function and reduce inflammation in affected muscles.
Key Questions Answered in the Polymyositis Pipeline Insight Report
The Polymyositis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for polymyositis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into polymyositis collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Global Clinical Trials Market
Rare Diseases Treatment Market
Report Coverage
The Polymyositis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into polymyositis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for polymyositis. The polymyositis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The polymyositis pipeline landscape will include an analysis based on efficacy and safety measures outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with polymyositis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to polymyositis.
Polymyositis Pipeline Outlook
Polymyositis is a rare inflammatory muscle disease characterized by chronic muscle inflammation and progressive weakness, primarily affecting the shoulders, hips, and neck. The exact cause remains unknown, though immune system dysfunction is believed to trigger muscle fiber damage. Symptoms often include fatigue, difficulty swallowing, and reduced mobility, significantly impacting daily activities.
Polymyositis treatment focuses on suppressing inflammation and improving muscle strength. Standard therapies include corticosteroids, immunosuppressants, and physical therapy to manage symptoms and prevent disease progression. PF1801, a novel long-acting glucagon-like peptide-1 receptor agonist, received FDA Orphan Drug designation in September 2021. It shows potential in improving muscle function in rare inflammatory myopathies.
Polymyositis Epidemiology
According to Tippawan Onchan et al., 2024, patients with idiopathic inflammatory myopathies (IIMs) exhibit lower survival rates compared to the general population, with early mortality ranging from 7.8% to 45%. Incidence rates vary across regions, reported at 7.7 cases per million in Asia and 2.18 cases per million in Israel. Overall, the global incidence ranges from 1.16 to 19 cases per million per year, with a prevalence of 2.4 to 33.8 per 100,000.
Polymyositis – Pipeline Therapeutic Assessment
This section of the report covers the analysis of polymyositis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
The polymyositis pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
- Polymers
- Vaccines
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II, with 40%, covers a major share of the total polymyositis clinical trials. It is followed by phase I at 36.73%, and phase III at 18.37%. This distribution indicates a robust pipeline, with a significant number of candidates advancing through early and mid-stage trials. The progression of these therapies holds promise for enhancing treatment options and improving patient outcomes in polymyositis.
Polymyositis Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the polymyositis pipeline analysis include small. The polymyositis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for polymyositis. Immune-targeted therapies are gaining traction in the polymyositis drug pipeline to address high unmet needs. For instance, AstraZeneca initiated the JASMINE Phase III trial in September 2024 to evaluate Saphnelo (anifrolumab) in patients with idiopathic inflammatory myopathies, including polymyositis. This therapy selectively inhibits type I interferon signaling, aiming to reduce muscle inflammation and improve patient outcomes, offering a disease-specific alternative to broad immunosuppressants and corticosteroids.
Polymyositis Clinical Trials – Key Players
The EMR report for the polymyositis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed polymyositis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in polymyositis clinical trials:
- Argenx
- Pfizer
- Paean Biotechnology Inc.
- AstraZeneca
- Immunoforge Co. Ltd.
- Restem, LLC.
- Miltenyi Biomedicine GmbH
- Cabaletta Bio
- NovelMed Therapeutics
- Priovant Therapeutics, Inc.
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for polymyositis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of polymyositis drug candidates.
Drug: PF-06823859
PF-06823859, sponsored by Pfizer, is an investigational drug being evaluated in a Phase 3 study for adults with active idiopathic inflammatory myopathies, including polymyositis and dermatomyositis. The study is examining how PF-06823859, administered as an intravenous infusion every four weeks, affects muscle strength, inflammation, and overall safety. This monoclonal antibody is designed to target immune-mediated muscle damage, aiming to improve mobility and reduce disease-related muscle weakness over a 48-week treatment period.
Biological: PN-101
PN-101, sponsored by Paean Biotechnology Inc., is an innovative allogeneic mitochondrial therapy derived from umbilical cord–derived mesenchymal stem cells. This Phase 2 trial is evaluating the efficacy and safety of PN-101 in patients with refractory polymyositis or dermatomyositis. The study is examining improvements in disease activity using IMACS-TIS at Week 12 compared with a placebo. PN-101 is administered as a single intravenous dose, aiming to restore cellular function and reduce inflammation in affected muscles.
Key Questions Answered in the Polymyositis Pipeline Insight Report
- Which companies/institutions are leading the polymyositis drug development?
- Which company is leading the polymyositis pipeline development activities?
- What is the current polymyositis commercial assessment?
- What are the opportunities and challenges present in the polymyositis pipeline landscape?
- What is the efficacy and safety profile of polymyositis pipeline drugs?
- Which company is conducting major trials for polymyositis drugs?
- Which companies/institutions are involved in polymyositis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in polymyositis?
The Polymyositis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for polymyositis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into polymyositis collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Global Clinical Trials Market
Rare Diseases Treatment Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Polymyositis
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Polymyositis
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Polymyositis: Epidemiology Snapshot
- 5.1 Polymyositis Incidence by Key Markets
- 5.2 Polymyositis – Patients Seeking Treatment in Key Markets
- 6 Polymyositis: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Polymyositis: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Polymyositis, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Polymyositis Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Polymyositis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Biological: EFG PH20 SC
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: PF-06823859
- 10.2.3 Other Drugs
- 11 Polymyositis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Biological: PN-101
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Other Drugs
- 12 Polymyositis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: DR-0201
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Polymyositis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Polymyositis, Key Drug Pipeline Companies
- 14.1 Argenx
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Pfizer
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Paean Biotechnology Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 AstraZeneca
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Immunoforge Co. Ltd.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Restem, LLC.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Miltenyi Biomedicine GmbH
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Cabaletta Bio
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 NovelMed Therapeutics
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Priovant Therapeutics, Inc.
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
